Targeted Protein Degradation
Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.
Alessio is Chair of Chemical and Structural Biology at the School of Life Sciences, University of Dundee. Alessio and his team have made significant contributions to the TPD field, including solving the first crystal structure of a PROTAC ternary complex. Initially in collaboration with the Crews Lab, they pioneered the structure-guided design of drug-like ligands for the von Hippel-Lindau E3 ligase, jump-starting the PROTAC field as a new therapeutic modality.
Alessio Ciulli PhD
Founder and Director
Raj joined Advent in 2005 bringing over 20 years of experience in biomedical research and as an entrepreneur and investor. After gaining an MA and DPhil from Oxford University, he pursued a successful academic career in molecular medicine before co-founding Oxford GlycoSciences (IPO on LSE and NASDAQ). Following its sale to UCB-Celltech, he became Chairman of Galapagos nv, a member of the Supervisory Board of the Novartis Venture Fund and a founding Director of Celldex Therapeutics. Since joining Advent, he has been involved with those portfolio Companies primarily engaged in the discovery of new medicines, including Avila, EUSA and Thiakis.
Raj Parekh DPhil
Nicki has over 25 years’ experience in pharmaceutical and biotechnology R&D in a variety of senior scientific and leadership roles. She was previously VP and Global Head of External Drug Discovery at F. Hoffmann-La Roche Ltd and prior to that, Senior Director, Business Development for GSK’s Centre of Excellence for External Drug Discovery (CEEDD). Nicki’s Biotech experience includes her role as Chair of the Board for Nanna Therapeutics Ltd, founding CEO of VirionHealth and Head of Drug Discovery at Syntaxin Ltd. She holds a PhD in Cell Biology from University College London.
Nicola Thompson PhD
After gaining a BSc and PhD from the University of Edinburgh, she pursued a career in clinical research with GSK and ILEX Oncology Inc before moving into a Business Development role in the higher education sector. Gaining experience in IP management, contract negotiation and account management, she was the founder of EDYN Creative Ltd which provides services to universities and industry in commercialising early stage innovations.
Wendy Nicholson PhD, MBA
After graduating from Loughborough University in 1997, Julia joined PricewaterhouseCoopers and qualified as a Chartered Accountant in 2001. For the last twelve years, as the founder and Managing Director of Archangel Accounting Ltd, Julia has provided tailor-made support to many companies, including those with venture capital backing, privately owned businesses and charities. In addition to Amphista Therapeutics Limited, other significant biotech sector clients include Healx Limited, AMO Pharma Limited, Ventus Medical Limited, Exvastat Limited, Encipher Biotherapeutics Limited, Pheno Therapeutics Limited, Curve Therapeutics Limited and Circadian Therapeutics Limited.
Julia Jones FCA, BSc
BioCity, Bo'Ness Rd, Newhouse, Chapelhall, Motherwell, ML1 5UH, UK
158-160 North Gower Street, London, England, NW1 2ND, UK